Ishita Drugs & Industries Downgraded to 'Sell' by MarketsMOJO on September 16, 2024

Ishita Drugs & Industries, a microcap pharmaceutical company, has recently been downgraded to a 'Sell' by MarketsMOJO on September 16, 2024. This decision was based on several factors, including weak long-term fundamental strength with an average Return on Equity (ROE) of 7.92%, poor long-term growth in net sales and operating profit, and a weak ability to service its debt with a poor EBIT to Interest ratio.
In addition, the company's recent results for June 2024 were flat and it has underperformed the market in the last year with a return of only 2.26%, compared to the market's return of 34.97%. However, there are some bullish factors for the stock, such as its technical trend improving from Mildly Bullish to -3.27% returns since August 30, 2024, and multiple indicators like MACD, Bollinger Band, and KST showing a positive trend.

The stock is currently trading at a fair value with a Price to Book Value of 2.4 and a PEG ratio of 0.7, indicating that it is not overvalued. It is also worth noting that the majority of shareholders are non-institutional investors.

Overall, while Ishita Drugs & Industries may not be performing well in the market currently, it is important to consider all factors before making any investment decisions. It is always recommended to do thorough research and consult with a financial advisor before making any investment in the stock market.